227 related articles for article (PubMed ID: 34074729)
1. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
[TBL] [Abstract][Full Text] [Related]
3. Protective role of the placental efflux transporter BCRP/ABCG2 in the relationship between prenatal cadmium exposure, placenta weight, and size at birth.
Barrett ES; Rivera-Núñez Z; Getz K; Ohman-Strickland P; Zhang R; Kozlosky D; Doherty CL; Buckley BT; Brunner J; Miller RK; O'Connor TG; Aleksunes LM
Environ Res; 2023 May; 225():115597. PubMed ID: 36863650
[TBL] [Abstract][Full Text] [Related]
4. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Vora B; Brackman DJ; Zou L; Garcia-Cremades M; Sirota M; Savic RM; Giacomini KM
Clin Transl Sci; 2021 Jul; 14(4):1431-1443. PubMed ID: 33931953
[TBL] [Abstract][Full Text] [Related]
5. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S; Aozasa N; Kotani H
Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
[TBL] [Abstract][Full Text] [Related]
7. In vitro identification of decreased function phenotype ABCG2 variants.
Suominen L; Sjöstedt N; Vellonen KS; Gynther M; Auriola S; Kidron H
Eur J Pharm Sci; 2023 Sep; 188():106527. PubMed ID: 37451410
[TBL] [Abstract][Full Text] [Related]
8. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
9. Interindividual Regulation of the Breast Cancer Resistance Protein/
Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
[TBL] [Abstract][Full Text] [Related]
11. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
[TBL] [Abstract][Full Text] [Related]
12. Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.
Gunness P; Aleksa K; Koren G
Can J Physiol Pharmacol; 2011 Sep; 89(9):675-80. PubMed ID: 21859328
[TBL] [Abstract][Full Text] [Related]
13. (67/68)Galmydar: A metalloprobe for monitoring breast cancer resistance protein (BCRP)-mediated functional transport activity.
Sivapackiam J; Harpstrite SE; Prior JL; Mattingly S; Sharma V
Nucl Med Biol; 2016 Mar; 43(3):191-7. PubMed ID: 26924499
[TBL] [Abstract][Full Text] [Related]
14. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
Ripperger A; Benndorf RA
Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
[TBL] [Abstract][Full Text] [Related]
16. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
[TBL] [Abstract][Full Text] [Related]
17. Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.
Szilagyi JT; Gorczyca L; Brinker A; Buckley B; Laskin JD; Aleksunes LM
Toxicol Sci; 2019 Apr; 168(2):394-404. PubMed ID: 30576553
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
[TBL] [Abstract][Full Text] [Related]
19. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
